OncoC4 announces first participant’s dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer’s disease

B ROCKVILLE, Md., April 9, 2026 /PRNewswire/ — OncoC4 Inc., a late clinical stage biopharmaceutical company, today announced first participant’s dosing following the clearance of the…
posteditor
posteditor
Articles: 16137

Other News